This release contains forward-looking information about Pfizer’s efforts to combat COVID-19, BioNTech’s potential COVID-19 mRNA vaccine, BNT162, a letter of intent regarding the co-development ...

Pfizer and BioNTech plan to share their booster data with the Food and Drug Administration in August and file for emergency use authorization shortly thereafter, a Pfizer spokesperson said.

Pfizer and partner BioNTech announced they have submitted a request on Friday to the U.S. Food and Drug Administration for emergency use authorization of their COVID-19 vaccine candidate.

Pfizer (PFE-1.64%) and BioNTech (BNTX-1.15%) together pulled off one of the greatest accomplishments in medical history by developing a safe and highly effective COVID-19 vaccine in only a matter ...

BioNTech is a German biotech and immunotherapy company that had pioneered tech using messenger RNA (more on this later) joined with Pfizer in 2018 to jointly develop an mRNA-based flu vaccine ...

Pfizer and BioNTech are supplying 300 million doses to the U.S. In addition to these two big supply deals, Pfizer and BioNTech have agreements in place with several other countries including ...

Pfizer and BioNTech are requesting emergency use authorization for their two-dose Covid-19 vaccine for children age 6 months up to 5 years, the companies said Tuesday.

Pfizer (PFE.N) and partner BioNTech (22UAy.DE) plan to ask U.S. and European regulators within weeks to authorize a booster dose of its COVID-19 vaccine, based on evidence of greater risk of ...

Pfizer and BioNTech said Tuesday they have submitted Covid-19 vaccine data on children ages 5 to 11 to the FDA for initial review, but are not yet seeking emergency use authorization.

The Pfizer-BioNTech emergency use authorization was based on clinical trials involving about 37,000 people. The full approval was based on study results involving more than 44,000 people followed ...

While Pfizer-BioNTech vaccine was fully approved as a two-shot regimen for those 16 and older, adolescents aged 12 to 15 can continue to be vaccinated under the vaccine’s emergency use ...

In children ages 5-11, the Pfizer-BioNTech vaccine was more than 90% protective against contracting symptomatic COVID-19, according to company data.